DDInter35 DDInter1658
A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38)
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Albendazole {u} (Compound) resembles {v} (Compound) Mebendazole
Albendazole {u} (Compound) binds {v} (Gene) ABCB1
Albendazole {u} (Compound) upregulates {v} (Gene) KIF14
Albendazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 1A Inducers
Albendazole {u} (Compound) downregulates {v} (Gene) GNPDA1
Albendazole {u} (Compound) causes {v} (Side Effect) Acute hepatic failure
Albendazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Albendazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dexamethasone
Albendazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carbamazepine
Albendazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nevirapine
Albendazole (Compound) resembles Mebendazole (Compound)
Albendazole (Compound) binds ABCB1 (Gene)
Albendazole (Compound) upregulates KIF14 (Gene)
Albendazole (Compound) is included by Cytochrome P450 1A Inducers (Pharmacologic Class)
Albendazole (Compound) downregulates GNPDA1 (Gene)
Albendazole (Compound) causes Acute hepatic failure (Side Effect)
Albendazole may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Albendazole may cause a minor interaction that can limit clinical effects when taken with Dexamethasone
Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine
Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Nevirapine